Pharma Journalist -

ReCode Therapeutics, a genetic medicines company using superior delivery to power the next wave of mRNA and gene correction therapeutics, announced it has signed a multi-year research…
Read More...

Boehringer Ingelheim and 3T Biosciences, announced they have entered into a strategic collaboration and licensing agreement to discover and develop next-generation cancer therapies to…
Read More...

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently operated subsidiary of Bayer AG, announced that it has signed a multi-year research collaboration and option…
Read More...

Synaffix B.V., a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs), announced the signing of…
Read More...

AstraZeneca’s Biologics License Application (BLA) for nirsevimab has been accepted for review by the US Food and Drug Administration (FDA) for the prevention of respiratory syncytial…
Read More...

Adcendo ApS, a biotech company focused on the development of breakthrough antibody-drug conjugates (ADCs) for the treatment of underserved cancers, announces a license agreement with…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that under the Accelerated Approval Pathway the U.S. Food and Drug Administration (FDA) has approved lecanemab-irmb (Brand Name in the U.S.:…
Read More...

AbbVie and Immunome, Inc. announced a worldwide collaboration and option agreement directed to the discovery of up to 10 novel antibody-target pairs arising from three specified tumor…
Read More...

Moderna, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create investigational mRNA-based conditionally activated therapies utilizing Moderna's…
Read More...

Moderna, Inc. and OriCiro Genomics K.K. announced they have entered into a definitive agreement through which Moderna will acquire OriCiro for $85 million. "With this acquisition, we…
Read More...